The deal follows the recent publication of the German researchers' study in the Journal of Nuclear Medicine. They developed radiopharmaceuticals based on gallium-68 (Ga-68), which they used to identify nearly 30 types of malignant tumors with greater uptake and improved image contrast.
These Ga-68 FAPI radiotracers can be labeled alternatively with different radioisotopes, depending on whether they are needed for diagnostic imaging or radiotherapeutic treatment, according to Dr. Uwe Haberkorn, co-inventor of FAPI and professor of nuclear medicine at the university.
"FAPI tracers may be beneficial for radiation therapy planning, suspicion of false-negative findings, staging, identification of primary tumors in patients with cancer of unknown primary or even therapy in the last-line situation, especially in combination with immunotherapy," he said in a statement. "In addition, FAPI imaging may also be used to assess and manage cardiac diseases or fibrotic diseases of the lung, liver, and kidneys."
Copyright © 2019 AuntMinnie.com